These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 8817828

  • 1. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus.
    McLain L, Durrani Z, Wisniewski LA, Porta C, Lomonossoff GP, Dimmock NJ.
    Vaccine; 1996 Jun; 14(8):799-810. PubMed ID: 8817828
    [Abstract] [Full Text] [Related]

  • 2. Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus.
    McLain L, Porta C, Lomonossoff GP, Durrani Z, Dimmock NJ.
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):327-34. PubMed ID: 7786579
    [Abstract] [Full Text] [Related]

  • 3. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization.
    Durrani Z, McInerney TL, McLain L, Jones T, Bellaby T, Brennan FR, Dimmock NJ.
    J Immunol Methods; 1998 Nov 01; 220(1-2):93-103. PubMed ID: 9839930
    [Abstract] [Full Text] [Related]

  • 4. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
    Cleveland SM, Buratti E, Jones TD, North P, Baralle F, McLain L, McInerney T, Durrani Z, Dimmock NJ.
    Virology; 2000 Jan 05; 266(1):66-78. PubMed ID: 10612661
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA.
    J Immunol; 1993 Jun 15; 150(12):5647-65. PubMed ID: 8515081
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41.
    Clerici M, Barassi C, Devito C, Pastori C, Piconi S, Trabattoni D, Longhi R, Hinkula J, Broliden K, Lopalco L.
    AIDS; 2002 Sep 06; 16(13):1731-41. PubMed ID: 12218383
    [Abstract] [Full Text] [Related]

  • 10. The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope.
    Buratti E, McLain L, Tisminetzky S, Cleveland SM, Dimmock NJ, Baralle FE.
    J Gen Virol; 1998 Nov 06; 79 ( Pt 11)():2709-16. PubMed ID: 9820146
    [Abstract] [Full Text] [Related]

  • 11. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP.
    J Infect Dis; 1993 Mar 06; 167(3):533-7. PubMed ID: 8095059
    [Abstract] [Full Text] [Related]

  • 12. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
    Parry C, McLain L, Dimmock NJ.
    AIDS Res Hum Retroviruses; 1994 Feb 06; 10(2):205-12. PubMed ID: 8198873
    [Abstract] [Full Text] [Related]

  • 13. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera.
    Vella C, Ferguson M, Dunn G, Meloen R, Langedijk H, Evans D, Minor PD.
    J Gen Virol; 1993 Dec 06; 74 ( Pt 12)():2603-7. PubMed ID: 7506299
    [Abstract] [Full Text] [Related]

  • 14. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.
    Broliden PA, von Gegerfelt A, Clapham P, Rosen J, Fenyö EM, Wahren B, Broliden K.
    Proc Natl Acad Sci U S A; 1992 Jan 15; 89(2):461-5. PubMed ID: 1370580
    [Abstract] [Full Text] [Related]

  • 15. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.
    Visciano ML, Diomede L, Tagliamonte M, Tornesello ML, Asti V, Bomsel M, Buonaguro FM, Lopalco L, Buonaguro L.
    Vaccine; 2011 Jul 12; 29(31):4903-12. PubMed ID: 21596074
    [Abstract] [Full Text] [Related]

  • 16. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
    Devito C, Zuber B, Schröder U, Benthin R, Okuda K, Broliden K, Wahren B, Hinkula J.
    J Immunol; 2004 Dec 01; 173(11):7078-89. PubMed ID: 15557206
    [Abstract] [Full Text] [Related]

  • 17. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.
    Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, Dawson PE.
    J Virol; 2006 Feb 01; 80(4):1680-7. PubMed ID: 16439525
    [Abstract] [Full Text] [Related]

  • 18. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R.
    J Virol; 2006 Feb 01; 80(3):1414-26. PubMed ID: 16415019
    [Abstract] [Full Text] [Related]

  • 19. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M, Qiao ZS, Montefiori DC, Haynes BF, Reinherz EL, Liao HX.
    AIDS Res Hum Retroviruses; 2005 Jan 01; 21(1):58-67. PubMed ID: 15665645
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.